Shares of Assembly Biosciences Inc (NASDAQ:ASMB) hit a new 52-week low on Monday . The stock traded as low as $13.13 and last traded at $14.80, with a volume of 81780 shares trading hands. The stock had previously closed at $18.79.
Several analysts have recently weighed in on the stock. BidaskClub upgraded shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, March 29th. Zacks Investment Research lowered shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, February 20th. Finally, Chardan Capital reiterated a “hold” rating and set a $30.00 target price on shares of Assembly Biosciences in a research report on Monday. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $43.00.
The stock has a market cap of $415.44 million, a P/E ratio of -4.09 and a beta of 1.75.
Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($1.03) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.91) by ($0.12). The firm had revenue of $3.74 million during the quarter, compared to analyst estimates of $3.69 million. Assembly Biosciences had a negative net margin of 613.02% and a negative return on equity of 57.48%. As a group, sell-side analysts expect that Assembly Biosciences Inc will post -4.61 earnings per share for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the business. Valeo Financial Advisors LLC boosted its position in Assembly Biosciences by 0.5% in the first quarter. Valeo Financial Advisors LLC now owns 201,000 shares of the biopharmaceutical company’s stock valued at $3,958,000 after buying an additional 1,000 shares in the last quarter. Tibra Equities Europe Ltd acquired a new position in Assembly Biosciences in the first quarter valued at about $918,000. Deutsche Bank AG boosted its position in Assembly Biosciences by 29.8% in the fourth quarter. Deutsche Bank AG now owns 54,606 shares of the biopharmaceutical company’s stock valued at $1,234,000 after buying an additional 12,525 shares in the last quarter. Capital Impact Advisors LLC boosted its position in Assembly Biosciences by 46.6% in the fourth quarter. Capital Impact Advisors LLC now owns 68,875 shares of the biopharmaceutical company’s stock valued at $1,524,000 after buying an additional 21,887 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Assembly Biosciences by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 228,069 shares of the biopharmaceutical company’s stock valued at $5,158,000 after buying an additional 12,055 shares in the last quarter. Hedge funds and other institutional investors own 83.77% of the company’s stock.
About Assembly Biosciences (NASDAQ:ASMB)
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
See Also: How do taxes affect a CDs total return?
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.